Laboratory Monitoring for Elderly Male Patients with Anemia and Non-Hodgkin's Lymphoma

Core Laboratory Tests

The American Society of Clinical Oncology recommends complete blood count with differential at every visit to monitor for bone marrow involvement, treatment-related cytopenias, and abnormal lymphocyte populations suggesting relapse 1
Comprehensive metabolic panel should be obtained to assess renal and hepatic function, particularly important in elderly patients receiving chemotherapy, and to detect electrolyte abnormalities that may indicate tumor lysis syndrome 1
The National Comprehensive Cancer Network suggests lactate dehydrogenase is a critical prognostic marker and should be monitored regularly to guide treatment decisions in elderly patients 2

Beta-2 microglobulin should be checked periodically as it serves as an important prognostic marker, especially in follicular lymphoma, and helps assess disease burden and progression risk 1, 3
Uric acid levels are important before and during treatment to monitor for tumor lysis syndrome risk and guide prophylactic management in active disease 1

The European Society for Medical Oncology recommends during active surveillance, CBC with differential every 3 months for the first 2 years, then every 6 months for 3 more years, and annually thereafter 4
During or immediately after treatment, CBC with differential should be monitored at each treatment cycle and at 3, 6, 12, and 24 months post-treatment 4

The Centers for Disease Control and Prevention recommends hepatitis B and C screening must be performed before initiating any anti-CD20 monoclonal antibody therapy due to reactivation risk 1, 2
HIV screening should also be performed 2, 3

The American Heart Association suggests if the patient received anthracycline-based chemotherapy, baseline and periodic cardiac function evaluation with echocardiography or MUGA scan should be performed 1, 5
Cumulative anthracycline dose in mg/m² should be documented 4, 5

The Endocrine Society recommends TSH levels should be checked at 1, 2, and 5 years if the patient received neck irradiation, particularly important in elderly patients with multiple comorbidities 4, 6

The American Society of Clinical Oncology advises against relying solely on physical examination to detect relapse; laboratory monitoring is essential even in asymptomatic patients 6
Performance status alone is insufficient for treatment decisions in elderly patients; laboratory markers provide objective data for fitness assessment 6